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Introduction: Myocardial infarction is accompanied by a significant loss of cardiomyocytes (CMs). Functional CMs,
differentiated from human embryonic stem cells (hESCs), offer a potentially unlimited cell source for cardiac disease
therapies and regenerative cardiovascular medicine. However, conventional production methods on monolayer
culture surfaces cannot adequately supply the large numbers of cells required for such treatments. To this end, an
integrated microcarrier (MC) bioprocessing system for hESC propagation and subsequent CM differentiation was
developed.
Methods: Production of hESC-derived CMs was initially established in monolayer cultures. This control condition
was compared against hESC expansion on laminin-coated MC with cationic surface charge, in a stirred serum-free
defined culture. Following expansion, the hESC/MC aggregates were placed in a CM differentiation medium, using
Wnt signalling modulators in four different culture conditions. This process eliminated the need for manual colony
cutting. The final optimized protocol was tested in stirred spinner flasks, combining expansion and differentiation
on the same MC, with only media changes during the culture process.
Results: In the propagation phase, a 15-fold expansion of viable pluripotent HES-3 was achieved, with homogeneous
sized aggregates of 316 ± 11 μm. Of the four differentiation conditions, stirred spinner flask cultures (MC-Sp) provided
the best controlled aggregate sizes and yielded 1.9 × 106 CM/ml, as compared to 0.5 × 106 CM/ml using the monolayer
cultures method: a four-fold increase in CM/ml. Similar results (1.3 × 106 CM/ml) were obtained with an alternative hESC
H7 line. The hESC/MC-derived CM expressed cardiac-specific transcription factors, structural, ion channel genes, and
exhibited cross-striations of sarcomeric proteins, thus confirming their cardiac ontogeny. Moreover, E-4031 (0.3 μM)
prolonged the QT-interval duration by 40% and verapamil (3 μM) reduced it by 45%, illustrating the suitability of these
CM for pharmacological assays.
Conclusions: We have demonstrated a robust and scalable microcarrier system for generating hESC-derived CM. This
platform is enabled by defined microcarrier matrices and it integrates cell propagation and differentiation within a
continuous process, in serum-free culture media. It can generate significant numbers of CM, which are potentially
suitable for future clinical therapies.* Correspondence: steve_oh@bti.a-star.edu.sg
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Cardiovascular disease is a major cause of deaths world-
wide [1]. Most of these diseases, such as ischemic heart
disease and myocardial infarction, are associated with
the permanent loss of heart muscle, in the form of func-
tional cardiomyocytes (CMs) [2]. Given the limited in-
trinsic regenerative capacity of the mammalian heart,
recent studies have focused on engineering the constitu-
ent cells for tissues that may potentially repair damaged
cardiac muscle. Cells intended for clinical use need to be
expanded easily in significant numbers and should dif-
ferentiate into mature, fully functional CMs, capable of
integrating to the damaged host tissue [3,4]. Human pluri-
potent stem cells (hPSCs), such as human embryonic stem
cells (hESCs) and human induced pluripotent stem cells,
offer the opportunity of a promising therapeutic ap-
proach in which functional CMs generated in vitro can
be transplanted into an injured heart and restore its
function [4-6].
hPSCs have been differentiated with growth factor-based
[7-10] or small molecule-based [11-15] differentiation
protocols. Recently, a highly efficient CM differentiation
protocol was reported by Lian and colleagues [12,13]. The
protocol uses two small molecules to modulate the Wnt
signalling pathway, with early enhancement of differenti-
ation at day 0 by 6-bromoindirubin-3′-oxime (BIO) or
CHIR99021 and subsequent repression of the Wnt path-
way, from day 3, by adding inhibitor of Wnt production
IWP2 or IWP4 [12]. Up to 98% cardiac troponin T
(cTnT)-positive functional human CMs was reported for
monolayer cultures (MNL) [12].
Pluripotent hESCs have been generally differentiated
in two different platforms either on tissue culture plates
[16-20] or embryoid body (EB) cultures [21,22]. The sus-
pended EB cultures have the potential for volumetric
scale-up [23,24], which poses significant challenges in
planar tissue culture plates [25]. However, the generation
of EBs involves dissociating or cutting aggregate cultures
and subsequent cell reaggregation [26]. These processes
are labour intensive and can affect cell viability, making
the process difficult to automate and scale up. Moreover,
it is hard to control aggregate sizes and shapes, and such
heterogeneity therefore affects differentiation reprodu-
cibility [27,28]. Although EBs of controlled size can be
formed by hanging drops [15] or forced aggregation
methods [29,30], they are limited to experiments on the
scale of a research laboratory. In addition, high produc-
tion costs, primarily generated by expensive growth fac-
tors [31], are not practical for large-scale manufacture.
These hurdles must be overcome in developing an opti-
mal method for production of large amounts of CMs as
recently reviewed by our group [31].
Scalable methods for expansion of hPSCs on commer-
cial microcarriers (MCs) coated with extracellular matrixproteins have been developed achieving high cell expan-
sion (eightfold to 18-fold) in long-term, robust, suspen-
ded cultures [32-34]. hPSCs retain pluripotent markers,
retain the ability to differentiate into the three primary
germ layers, and exhibit normal diploid karyotypes. Re-
cently, a defined polystyrene-based (≈100 μm diameter)
MC coated with cationic poly-L-lysine (PLL) polyelectro-
lyte and laminin (LN) was developed by our group [35].
This defined matrix supports the expansion of HES3, H7,
and IMR90 under continuous agitation from a single-cell
seeding solution achieving high cell yields (14-fold, eight-
fold, and sevenfold cell expansion, respectively) with ex-
cellent viability (>90%). Importantly, uniform size (320
to 420 μm) hPSC/MC aggregates are generated during
growth in agitated spinner flasks. These aggregates may be
used as EBs for further differentiation into specific cell
lineages, thus eliminating the need for cell dissociation,
cutting, and reaggregation. Our group has similarly devel-
oped an integrated MC propagation and differentiation
platform for neuroprogenitors, with yields 11.6-fold higher
than those from EB culture [36].
The present study implements uniform-sized aggre-
gates, formed during stirred spinner culture using MCs
coated with PLL + LN, to generate CMs within a conti-
nuous process, in the same culture vessel. The differenti-
ation of these hESC/MC aggregates was directed to CMs
using a differentiation protocol based on Wnt modulators
[12,13]. Five culture regimes were evaluated, ranging from
benchmarking with MNL to MC-based cultures in static
conditions and under agitation (Figure 1). The efficiency
of cardiac differentiation was quantified and the mole-
cular, structural, and functional properties of hESC/MC-
derived CMs were also examined. This study provides a
foundation for the scalable and robust production of
hESC-derived CMs in large numbers, by means of a con-
joint propagation and differentiation bioprocess in a de-
fined environment, free of growth factors.
Materials and methods
Microcarriers and their coatings
Polystyrene MCs with an average diameter of 97 ± 10 μm
were purchased from Thermo-Fisher Scientific (Waltham,
MA, USA). These MC beads were sterilised by exposure to
gamma irradiation (10 minutes, 10 kGray/hour) in a 60Co
irradiator (Gammacell 200 Excel; Ottawa, ON, Canada)
before being utilised for culture.
For coating with PLL (70 to 150 kDa; Sigma-Aldrich,
St. Louis, MO, USA), 12 μl of 1 mg/ml PLL were added
to 20 mg MC in 600 μl phosphate-buffered saline (PBS),
to make a final PLL concentration of 20 μg/ml. This was
incubated at 4°C overnight and then rinsed with PBS
before further coating. Similarly, the coating of murine
LN (Life Technologies, Carlsbad, CA, USA) was
achieved by adding 20 μl of 1 mg/ml LN to 20 mg PLL-
Figure 1 Schematic presentation of the experimental plan to evaluate cardiomyocyte differentiation via monolayer and human
embryonic stem cell/microcarrier aggregates cultures. Morphological representation of the derived cardiomyocytes from the different culture
regimes. Scale bars: 500 μm for human embryonic stem cell (hESC)/microcarrier (MC) aggregate cultures, and 100 μm for the two-dimensional
(2D) monolayer hESC cultures. MC-AS, hESC/MC aggregates in agitated suspension cultures; MC-Rp, monolayer replated cultures; MC-Sp, hESC/MC
aggregates in spinner cultures; MC-SS, hESC/MC aggregates in static suspension cultures; TC, tissue culture.
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tion of 33 μg/ml [35]. The MCs were similarly incubated
at 4°C overnight, followed by a rinse with PBS before be-
ing used for cell culture.Culture of human embryonic stem cells
The HES3 ([46 X,X]; ES Cell International, Alameda,
CA, USA) and H7 ([46 X,X]; WiCell Research Institute,
Madison, WI, USA) cell lines were routinely maintained
on Matrigel-coated plates using mTeSR™1 hESC medium
(StemCell Technologies, Vancouver, BC, Canada) as
described previously [35,37]. Cultures were incubated
at 37°C in a humidified atmosphere with 5% carbon
dioxide. Unless otherwise stated, all culture media (for cell
propagation and differentiation) and supplements were
purchased from Life Technologies and all reagents and
chemicals were purchased from Sigma-Aldrich.Human embryonic stem cell propagation in spinner cultures
hESC MC culture was run in a 50 ml spinner flask
(BellCo, Vineland, NJ, USA), using a procedure similar
to the one described previously [32,35]. Briefly, hESC/
MC aggregates from six-well ultra-low attachment
plate (Costar, Tewksbury, MA, USA) cultures were
mechanically dissociated into small cell clumps and
seeded at 2 × 105 cells/ml in the 50 ml spinner flask
that contained 25 ml hESC medium and 200 mg PLL
+ LN-coated MC. The sample was incubated at 37°C/
5% carbon dioxide for 24 hours in static conditions,
after which another 25 ml hESC medium were added
and the culture was then agitated at 30 rpm for
6 days. Eighty per cent of the spent medium was re-
placed daily with fresh hESC medium. The cell con-
centration and cell viability were determined daily using a
Nucleocounter NC-3000 (Chemometec, Davis, CA, USA).
Pluripotent markers were measured by flow cytometry on
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from images taken using an Olympus IX70 microscope
(Olympus, Shinjuku-ku, Tokoyo, Japan), with average di-
mensions determined using NIH image J software [35].
Direct cardiomyocyte differentiation from propagated
hESCs via temporal modulation of canonical Wnt
signalling
To induce CM differentiation, the direct differentiation
protocol from Lian and colleagues that uses small
molecule, CHIR99021 (Selleck, Houston, TX, USA) and
IWP2 (Stemgent, Cambridge, MA, USA), modulators of
Wnt signalling was adopted [12,13] and optimised (see
Additional file 1). This was implemented in five culture
regimes (Figure 1): MNL, replated hESC/MC aggregate
cultures (MC-Rp), hESC/MC aggregates in static sus-
pension cultures (MC-SS), hESC/MC aggregates in agi-
tated suspension cultures (MC-AS), and hESC/MC
aggregates in spinner cultures (MC-Sp). Contracting
monolayers and beating aggregates were visualised daily
under phase-contrast microscopy (Evos, AMG, Mill
Creek, WA, USA). On day 20 of the differentiation proto-
col, cells from all cultures were harvested and analysed by
fluorescence-activated cell sorting (FACS). The sizes of
differentiated aggregates were measured using the Olym-
pus IX70 microscope, and average sizes were determined
using NIH image J software.
Culture regime 1: monolayer
A hESC single-cell suspension was obtained by dissociat-
ing confluent HES3 with TrypLE™ (Life Technologies).
Viable cells (4 × 105 cells/well) from the single cell sus-
pension were seeded into a 12-well plate (Corning,
Tewksbury, MA, USA) coated with 10 μg/ml LN. The
cultures were maintained in mTeSR™1 hESC medium in
a 37°C/5% carbon dioxide incubator for 3 to 4 days, untilFigure 2 Effects of different agitation and static modes in the differen
of times. X, aggregate disintegration; √, successful aggregate growth.cells reached confluence. At this point, differentiation
was started by removing spent hESC medium and add-
ing RPMI/B27 medium without insulin (referred to as
differentiation medium) and containing 12 μM
CHIR99021 [12]. After 24 hours (that is, day 1 of differ-
entiation), the medium was aspirated and replaced with
fresh differentiation medium. On day 3 of differentiation,
differentiation medium with 5 μM IWP2 was added. On
day 5 of differentiation, the IWP2-containing differenti-
ation medium was removed and the medium was subse-
quently refreshed every 2 days, until day 11. Cells were
then maintained in differentiation medium with insulin
until day 20.Culture regime 2: replated hESC/MC aggregates
About 50 hESC/MC aggregates (equivalent to 4 × 105
cells/well) from spinner flask cultures were inoculated
onto a 10 μg/ml LN-coated 12-well plate. After incuba-
tion for 1 day to allow the aggregates to attach, the plate
was washed with PBS to remove unattached aggregates.
Direct differentiation was subsequently initiated by re-
moving spent hESC medium and adding differentiation
medium containing 15 μM CHIR99021 (day 0). After
24 hours the differentiation medium was replenished,
and 10 μM IWP2 was added at day 3. This IWP2 was re-
moved during the medium exchange on day 5. Cells
were then maintained in differentiation medium with
insulin from day 11 until day 20.Culture regime 3: hESC/MC aggregates in static suspension
About 50 hESC/MC aggregates from spinner cultures
were incubated in a 12-well ultra-low attachment plate
(Nunc, Rochester, NY, USA) and directly subjected to
cardiac differentiation simply by changing the hESC
medium into CHIR99021-containing differentiationtiation phase. Agitation at 110 rpm was applied at different periods
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MC-Rp above.
Culture regime 4: hESC/MC aggregates in agitated suspension
The same medium was used as in MC-SS with different
times for static and agitation (110 rpm) during the
period of differentiation, as shown in Figure 2. The suc-
cessful protocol was static on day 1, agitated on day 2,
static again on day 3, and agitated for days 4 to 20.
Culture regime 5: hESC/MC aggregates in stirred spinner
culture
The best agitation protocol chosen from MC-AS was
transposed to culture in a spinner flask. Briefly, hESC/
MC aggregates from the exponentially growing hESC
MC culture (1.5 × 106 cells/ml) were used. Differentiation
was initiated by replacing the spent hESC medium with
differentiation medium containing 15 μM CHIR99021.
This was incubated in static condition for 16 hours, after
which the medium was replaced with fresh differentiation
medium (without CHIR99021) and stirred at 30 rpm. On
day 3, differentiation medium with 10 μM IWP2 was in-
troduced and incubated with a second static 16-hour
pause, followed by agitation from day 4 until the end of
the differentiation process (day 20). On day 5 the spent
medium was replenished, and refreshed thereafter every
2 days until day 11. The culture was then fed with differ-
entiation medium with insulin every 2 days until day 20.
Aliquots (~1 ml) of cell suspension were taken at different
time points for gene expression analysis. On day 20,
the culture was harvested for structural and functio-
nal analyses.
Fluorescence-activated cell sorting
To test the pluripotency of expanded hESCs, FACS was
performed with the expression of the stem cell markers
Tra-1-60 (Millipore, Darmstadt, Germany) and mAb84
[34] by flow cytometry as described in our previous
studies [33,35].
CM differentiation efficiency was quantified by the
expression of myosin heavy chain (MHC) and cTnT I.
Briefly, cells harvested from day 20 were fixed and per-
meabilised using Fix and Perm Cell permeabilisation re-
agents (Life Technologies). The cells were subsequently
incubated with anti-MHC (dilution 5:200; Developmental
Studies Hybridoma Bank, Iowa city, IA, USA) and anti-
cTnT (dilution 1:200; Millipore) for 20 minutes. After
washing with 1% bovine serum albumin/PBS, the cells
were incubated in the dark with 1:500 dilutions of anti-
mouse FITC-conjugated secondary antibodies (dilution
1:500; DAKO, Glostrup, Denmark) for 20 minutes in the
dark. The signal from labelled cells was acquired using a
FACSCalibur and was analysed with FlowJo (Tree Star,
Ashland, OR, USA), following the manufacturer’sprotocol, with gating selected at the point of intersection
between the marker and its isotype control [38].
Quantitative polymerase chain reaction
Total RNA was isolated from undifferentiated (day 0)
and differentiating (at different time points until day 20)
hESCs from MNL and hESC/MC aggregates from MC-Sp.
This isolation was accomplished using the RNeasy mini
kit (Qiagen, Hilden, Germany). The yield and purity of the
RNA were determined with a NanoDrop spectrophotom-
eter (NanoDrop Technologies). RNA (1 μg) was reverse
transcribed into cDNA via Oligo(dT) with SuperScript
III Reverse Transcriptase (Life Technologies). Real-time
quantitative polymerase chain reaction was performed on
an ABI7500 system (Applied Biosystems, Carlsbad, CA,
USA) with Power SYBR Green PCR Master Mix (Applied
Biosystems) containing the genes of interest presented in
Additional file 2. Thermal cycling was applied as follows:
50°C for 2 minutes, 95°C for 10 minutes, following by
40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
Data were analysed and the fold-change of each gene refer-
enced against expression of the same gene prior to cell
differentiation.
Metabolite measurement
Glucose, glutamine, lactate, and ammonia concentrations
in the cultures were measured using Bioprofile 100 plus
(NOVA, Waltham, MA). Measurements were performed
on both spent media and its replacement fresh medium
after each medium change. Specific consumption and pro-
duction rates of the metabolites and yield ratios were cal-
culated as described in Chen and colleagues’ paper [39],
by averaging of triplicate experiments.
Immunocytochemistry
Beating hESCs from MNL and hESC/MC aggregates
from MC-Sp were harvested and washed in PBS, and
replated in Matrigel-coated 24-well plates (Corning),
where they were cultured for 2 days. The cells were then
fixed with 4% paraformaldehyde for 15 minutes at room
temperature, rinsed in PBS, and permeabilised by incu-
bation with 0.1% Trion X-100/1% bovine serum albumin
in PBS for 1 hour at room temperature. They were then
blocked for 2 hours in PBS containing 0.1% Triton
X-100, 10% goat serum, and 1% bovine serum albumin.
Cells were then probed with primary antibodies including
anti-sarcomeric α-actinin (anti-SA; Sigma, St. Louis, MO,
USA), anti-myosin light chain (Cell Signalling, Danvers,
MA, USA), and anti-cTnT (Millipore) for 1 hour,
followed by a secondary Alexa Fluor® 594 antibody
(Life Technologies) for another 2 hours at room
temperature. A fluorescent mounting medium with 4′,6-
diamidino-2-phenylindole nuclear staining (Vectashield)
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Axiovert 200 M fluorescence microscope (Carl Zeiss).
QT prolongation assay by microelectrode arrays
Beating hESC/MC aggregates were incubated with
TrypLE™ Express (Life Technologies) for 30 minutes
to dissociate the cells from microcarriers. The cell suspen-
sions were then filtered through a 40-μm cell strainer
(Becton Dickinson, San Jose, CA, USA) and placed in an
ultra-low attachment U-96 plate (Costar). They were cen-
trifuged at 1500 rpm for 5 minutes and subsequently
allowed to form EB-like aggregates for 2 to 3 days until
the aggregates resumed beating contractions. The EB-like
aggregates were then transferred to ReproCELL Inc.,
Kanagawa, Japan, who applied their QT prolongation
(QTempo) assay on a microelectrode array system. A
detailed description of the microelectrode array system is
published elsewhere [40,41]. The results obtained from
this system are comparable with the patch clump system
[40]. Briefly, the assay consisted of plating the aggregate
on a microelectrode array dish (MEA200/30iR-Ti-gr;
Multi Channel Systems, Reutlingen, Germany) in
QTempo assay medium supplemented with E-4031 or
verapamil with increasing concentrations. Each con-
centration of test compound was added to the beating
aggregate every 4 minutes in an accumulative assay
method [38,40]. Two minutes (minutes 0 to 2) were
allowed for conditioning, followed by 2 minutesFigure 3 Growth kinetics of HES3/microcarrier aggregates differentiat
and 5% carbon dioxide in stirring conditions, except on day 1 and day 3 in
reduce cell loss due to the addition of Wnt modulators, CHIR99021 and IW(minutes 2 to 4) for detection, as per ReproCELL’s
QTempo assay protocol [40]. Commercially available
induced pluripotent stem cell-derived CM (ReproCardio
2) from ReproCELL Inc. was used as positive control. QT
intervals (also known as the field potential duration [42])
were determined by measuring the time interval between
the beginning of the Q wave and the end of the T wave on
the electrocardiogram [43]. The correction of the QT
interval for the beating rate is calculated according to
Bazett’s formula [44].Statistical analysis
All experiments were performed at least in triplicate.
Data values are reported as the mean and standard devi-
ation. Analysis of variance was applied as a comparison
between groups, with P < 0.05 and P < 0.01 considered
two levels of statistically significant differences.Results
Differentiation of hESCs to cardiomyocytes via
conventional monolayer cultures
HES3 cells were differentiated into CMs using a Wnt
modulator-based protocol, as described by Lian and col-
leagues [12]. The culture matrix was LM rather than
Matrigel™, however, in order to develop a defined envir-
onment that is suitable for generating and maintaining
clinical-grade CMs.ing in stirred spinner cultures. The cultures were incubated at 37°C
which the cultures were incubated in static conditions for 16 hours to
P2. Feeding regime as indicated by arrows.
Table 1 Propagation and differentiation of HES3 to cardiomyocytes using different culture methods
Culture conditions MNL hESC cultures hESC/MC aggregate spinner cultures
Propagation (7 days)
Expansion fold (propagation) 10.3 ± 0.4 15.4 ± 0.4
% Pluripotent cells
Tra-1-60-positive 93.1 ± 1.4 96.2 ± 1.7
mAb84-positive 99.4 ± 0.5 98.6 ± 1.7
Aggregate sizes (μm) NA 316 ± 11
Differentiation to cardiomyocytes (20 days)
MNL MC-Rp MC-SS MC-AS MC-Sp
Expansion fold (differentiation) 2.0 ± 0.2 2.2 ± 0.1 2.1 ± 0.2 2.0 ± 0.2 2.3 ± 0.1
% beating aggregates Beating sheet 65.7 ± 1.8 (beating foci on plate) 66.5 ± 2.6 53.4 ± 1.5 73.6 ± 2.8
Beating aggregate size (μm) NA NA 1063 ± 53 581 ± 54 655 ± 13
% Cardiomyocytes
MHC-positive 45.7 ± 4.6 43.1 ± 1.2 42.6 ± 1.9 42.8 ± 1.6 47.7 ± 1.9
cTnT-positive 51.1 ± 0.5 53.1 ± 0.9 45.7 ± 2.9 42.4 ± 0.2 56.1 ± 1.4
CM/hESC 3.8 ± 0.2 1.2 ± 0.2 1.0 ± 0.2 0.8 ± 0.1 9.6 ± 0.3a
CM/ml (×x106) 0.5 ± 0.02 0.2 ± 0.02 0.1 ± 0.02 0.1 ± 0.01 1.9 ± 0.05b
Total expansion fold (propagation + differentiation) 20.0 ± 0.8 32.8 ± 1.1 31.8 ± 2.1 29.3 ± 2.5 34.3 ± 0.9c
HES3 cells were propagated as either monolayer cultures (MNL) or human embryonic stem cell (hESC)/microcarrier (MC) aggregates for 7 days. Five differentiation
culture regimes were tested. Data presented are mean ± standard deviation (n = 3 to 4). In HES3 cultures: asignificant difference between MC-Sp and MNL
(P < 0.05), and between MC-Sp and the other three regimes (P < 0.01), in terms of cardiomyocytes produced per initial hESC seeded (CM/hESC); bsignificant
differences (P < 0.01) between MC-Sp and the other four regimes in terms of cardiomyocyte density (CM/ml); csignificant difference between MC-Sp and MNL
(P < 0.05) in terms of total expansion fold achieved. CM, number of cardiomyocytes (cTnT-positive cells) in the final cell population; Total expansion fold, cell
expansion from seeding the hESC culture in the propagation phase, to final CM harvesting (day 20) in the differentiation phase. cTnT, Cardiac troponin T; MC-AS,
hESC/MC aggregates in agitated suspension cultures; MC-Rp, monolayer replated cultures; MC-Sp, hESC/MC aggregates in spinner cultures; MC-SS, hESC/MC
aggregates in static suspension cultures; MHC, myosin heavy chain; NA, not available.
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and IWP2 for cardiac differentiation were 12 μM and
5 μM, respectively (see Figure S1A in Additional file 1).
Spontaneously contracting regions were readily observed
at 8 days’ differentiation. The numbers of contracting
foci increased with time, and at day 20 these were ob-
served over almost the entire well (see Additional file 3).
These foci appeared to be loosely attached to the plate.
On day 20 of differentiation, total cell expansion (cell ex-
pansion from seeding the hESC culture in the propaga-
tion phase to final CM harvesting in the differentiation
phase) was 20 ± 0.8-fold. Furthermore, 45.7 ± 4.6% of cells
were MHC-positive and 51.1 ± 0.5% were cTnT-positive
as measured by FACS (Table 1). The overall CM yield was
3.8 ± 0.2 CM/hESC, with a final cell concentration of
0.5 ± 0.02 × 106 CM/ml.
Differentiation of spinner culture expanded hESC/MC
aggregates into cardiomyocytes by four different
approaches
HES3 cells were first propagated on PLL + LN-coated
MCs in mTeSR™1 for 7 days on MC cultures in 50 ml
stirred spinner flasks. Similarly to our previous work
[35], exponential cell growth started on day 4, with a
maximum cell density of ~3 × 106 cells/ml attained atday 7. Cell viability was above 90% (see Figure S2A in
Additional file 4), with high expression (>90%) of pluri-
potent markers Tra-1-60 and mAb84 (Table 1). Spherical
hESC/MC aggregates (EB-like), 316 ± 11 μm in size,
were generated (Table 1; see Figure S2A in Additional
file 4).
After cell propagation, four methods of differentiation
for cardiogenesis efficiency were investigated by mo-
dulating Wnt [12,13] – replated hESC/MC aggregates
on LN-coated plates (MC-Rp); hESC/MC aggregates in
static suspension (MC-SS); hESC/MC aggregates in agi-
tated suspension (MC-AS); and hESC/MC aggregates in
spinner cultures (MC-Sp) – as illustrated in Figure 1.
Replated hESC/MC aggregates
hESC/MC aggregates attached and subsequently spread
within 3 to 4 days, forming a flattened configuration
on the LN-coated surface. About 50% of the MCs
were released to culture supernatant after cell plating
and during differentiation. Beating clusters were first
observed as early as day 8, following incubation with
15 μM CHIR99021 and 10 μM IWP2 (see Figure S1B in
Additional file 1). On day 20, 65.7 ± 1.8% of beating clus-
ters, lying on beating sheets were scored. Total CM yield
was 1.2 ± 0.2 CM/hESC and density was 0.2 ± 0.02 × 106
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However, the total expansion was 32.8 ± 1.1-fold, higher
than that in MNL (20.0 ± 0.8-fold; P < 0.05; Table 1).
hESC/MC aggregates in static suspension
Despite the optimal concentrations of CHIR99021 and
IWP2 (see Figure S1C in Additional file 1) being used,
which were the same as for MC-Rp, beating aggregates
were observed later, around day 12 of differentiation.
On day 20, the CM density was 0.1 ± 0.02 × 106 CM/ml.
Moreover, uncontrolled agglomeration of cell aggregates
was observed, resulting in the formation of large aggre-
gates, 1,063 ± 53 μm in size (Table 1). In terms of total
expansion, the percentage of beating aggregates scored,
and the fraction of MHC-positive and cTnT-positive
cells stained, MC-SS yielded similar results to MC-Rp
(Table 1).
hESC/MC aggregates in agitated suspension
To prevent the formation of very large aggregates during
the differentiation phase of MC-SS, agitation at 110 rpm
was applied. However, the induced shear stress resulted in
massive cell detachment 1 day after adding CHIR99021
(Figure 2). To mitigate this, a static pause (optimally ~16
hours) was introduced after the addition of CHIR99021.
This was followed by 2 days of agitation and another static
pause (~16 hours) when IWP2 was added, since aggregate
dissociation was observed if the culture was continuously
agitated (Figure 2). After these two periods, the culture
was placed under continuous agitation. At day 20, 53.4 ±
1.5% of aggregates were beating, 42.8 ± 1.6% of cells were
MHC-positive, and 42.4 ± 0.2% of cells were cTnT-positive,
yielding 0.8 ± 0.1 CM/hESC, and a cell concentration of
0.1 ± 0.01 × 106 CM/ml, similar to the CM yield from
MC-SS, but with smaller beating aggregates (581 ± 54 μm)
(Table 1).
To summarise, we demonstrated that hESC/MC ag-
gregates can serve as EBs for cardiac differentiation with
higher differentiation efficiency. The efficiency between
the three culture regimes did not vary to a great extent
(0.8 to 1.2 CM/hESC; Table 1). To implement this proto-
col in bioreactors used for industrial manufacturing, a
regime consisting of agitation with intermittent static
pauses was introduced. This culture regime retained in-
tact aggregates for differentiation and was applied there-
fore for direct differentiation in a stirred spinner flask.
hESC/MC aggregates in spinner cultures
After demonstrating the feasibility of generating CMs
using hESC/MC aggregates in agitated small plates, the
next step was to accomplish a conjoint propagation and
differentiation process in a stirred spinner flask (MC-Sp).
At day 20 of differentiation, this method yielded 73.6 ±
2.8% of beating aggregates (see Additional file 5). Theiraverage size was 655 ± 13 μm, approximately twice the lin-
ear dimensions (316 ± 11 μm) of aggregates during the ex-
pansion phase (Table 1). FACS analysis showed that up to
47.7 ± 1.9% of cells were MHC-positive and 56.1 ± 1.4% of
cells were cTnT-positive. This yielded 9.6 ± 0.3 CM/hESC,
about 2.5 times higher than the MNL cultures (3.8 ± 0.2
CM/hESC; P < 0.05) and eight to 12 times higher than the
MC-Rp, MC-SS and MC-AS (1.2 ± 0.2, 1.0 ± 0.2, and 0.8 ±
0.1 CM/hESC, respectively; P < 0.01). A CM concentration
of 1.9 ± 0.05 × 106 CM/ml was achieved, about four times
higher than the MNL (0.5 ± 0.02 × 106 CM/ml; P < 0.01),
nine times higher than the MC-Rp (0.2 ± 0.2 × 106 CM/ml;
P < 0.01), and 19 times higher than the MC-SS and MC-
AS (around 0.1 × 106 CM/ml; P < 0.01) (Table 1).Cell growth kinetics
The kinetics of HES3 cell growth during the differen-
tiation phase is shown in Figure 3. At day 1 of static cul-
ture (after addition of CHIR99021), about 30% cell death
occurs and cell density gradually increased thereafter.
The lag phase, before the onset of rapid cell expansion,
lasts about 3 to 4 days. This is similar to that observed
for the expansion phase of HES3 on MC in spinner
flasks (see Figure S2A in Additional file 4). Concomi-
tantly during this lag phase, lower expression of
octamer-binding transcription factor (OCT4) and a higher
expression of Brachyury T were observed (Figure 4). This
may signal the beginning of differentiation, with lower
hESC pluripotency and increasing mesoderm progenitors
[45]. The onset of exponential cell growth occurred be-
tween days 5 and 7, and maximum cell density (~3.4 × 106
cells/ml) was reached on day 17, followed by a stationary
phase in cell expansion. The doubling time was 128 ±
14 hours during the differentiation phase, as compared
with 27 ± 2 hours during the expansion phase (Table 2;
P < 0.001).
A second hESC cell line, H7, was used to test this con-
joint propagation (see Figure S2B in Additional file 4)
and differentiation platform (see Additional file 6). H7
cells propagated on PLL + LN MC cultures achieved cell
yields of ~2.3 × 106 cells/ml (see Figure S2B in Additional
file 4) or 12-fold cell expansion, generating hESC/MC ag-
gregates with dimensions of 418 ± 17 μm (see Additional
file 7). H7/MC aggregates subsequently differentiated into
CMs showed a similar differentiation pattern to HES3, yet
achieved a cell density of ~3 × 106 cells/ml (see Additional
file 6), with a doubling time of 151 ± 1 hours (Table 2).
H7/MC aggregates during the differentiation phase
were larger than the HES3/MC aggregates (Table 1 vs.
Additional file 7). The size of the aggregates may influence
the differentiation efficiency [27,29,38], giving rise to a
final output of 6.6 ± 0.4 CM/hESC initially seeded in the
culture and a cell concentration of 1.3 ± 0.09 × 106 CM/ml
Figure 4 Temporal gene expression pattern during cardiomyocyte differentiation in monolayer cultures and MC-Sp. Real-time quantitative
polymerase chain reaction data for various hallmark markers of cardiomyocyte differentiation (at days 1, 3, 5, 11, 13, 15, 17, and 20): squares, monolayer
cultures (MNL); diamonds, hESC/MC aggregates in spinner cultures (MC-Sp). Data are presented as the relative gene expression levels of differentiated
hESCs compared with the undifferentiated state. hESC, human embryonic stem cell; MC, microcarrier.
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MC-Sp (Table 1).
Metabolic measurements
Data for the consumption of glucose and glutamine as
well as the production of lactate and ammonia were
measured for HES3 and H7 in the expansion and diffe-
rentiation phases of MC-Sp, as shown in Table 2. The
metabolic activity of both hESC lines was considerably
lower during the differentiating phase, with respect totheir expansion phase. The molar ratio of produced
lactate to consumed glucose, YLac/Glc, is almost 2
(1.72 ± 0.14) during the HES3/MC expansion phase.
This indicates that cell respiration was mostly anaer-
obic [46], as compared with the differentiation phase,
where a lower YLac/Glc (1.34 ± 0.04) suggests that cells
tend to generate ATP through oxidative phosphoryl-
ation via aerobic metabolism. In contrast, values of
YAmm/Gln in both the expansion and differentiation
phases were similar (0.80 ± 0.02 and 0.70 ± 0.04,
Table 2 Doubling times, specific metabolic rates and yield ratios of hESCs in MC-Sp in propagation and
differentiation phases
HES3 cultures H7 cultures
Propagation Differentiation Propagation Differentiation
Double time (hours) 27 ± 2 128 ± 14 28 ± 2 151 ± 1
Specific consumption and production rate (mmol/109 cells/hour)
qGlc 0.36 ± 0.04 0.24 ± 0.02 0.34 ± 0.05 0.18 ± 0.02
qLac 0.63 ± 0.12 0.32 ± 0.02 0.57 ± 0.08 0.23 ± 0.01
qGln 0.036 ± 0.003 0.033 ± 0.001 0.028 ± 0.006 0.029 ± 0.003
qAmm 0.029 ± 0.003 0.023 ± 0.002 0.019 ± 0.005 0.016 ± 0.002
Yield ratio
YLac/Glc 1.72 ± 0.14* 1.34 ± 0.04* 1.66 ± 0.01* 1.27 ± 0.06*
YAmm/Gln 0.80 ± 0.02 0.70 ± 0.04 0.67 ± 0.03 0.55 ± 0.01
Glucose (Glc), lactate (Lac), glutamine (Gln), and ammonia (Amm) were measured using Bioprofile 100 plus. Specific consumption and production rates of the
metabolites (qm) were expressed as number of moles of metabolite consumed or produced per cells in one hour. Yield ratio (Ya/b) was calculated by the value of
qa over qb. *P < 0.05 indicated there is a significant difference between the values of YLac/Glc in the propagation phase and the differentiation phase in both HES3
and H7 cultures. MC-Sp, human embryonic stem cell/microcarrier aggregates in spinner cultures.
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mammalian cells (0.7 to 0.84) [39,46]. Similar results
were observed for H7 MC-Sp.
Molecular and structural characterisation
The dynamics of gene expression in hESC/MC aggregates,
during the differentiation phase of MC-Sp, and in hESCs
from differentiation MNL were monitored by quantitative
polymerase chain reaction. The cardiac gene expression
profile of the CMs derived from MNL (Figure 4) is similar
to the profile reported in the literature [12]. The kinetic
trends of all gene expression are similar in both MNL andFigure 5 Immunostaining of structural proteins in monolayer cultures
cultures (MNL) and (B) hESC/MC aggregates in spinner cultures (MC-Sp). N
Scale bar represents 50 μm. CM, cardiomyocytes; cTnT, cardiac troponin T;
chain; SA, sarcomeric α-actinin protein.MC-Sp. However, a delay in the decline of the pluripo-
tency marker and an increase of cardiac mesoderm as well
as progenitor gene expression was observed in MC-Sp.
The onset of CM differentiation was marked by a decrease
in the pluripotency marker, OCT4, following the replace-
ment of culture medium with differentiation medium
(containing CHIR99021) at day 0. This marker decreased
to negligible levels by day 11. The expression of mesoderm
marker, Brachyury T, was transient. It peaked on day 3
and returned to its baseline expression by day 11.
This simultaneous decrease in OCT4 and increase in
Brachyury T was observed during the lag phase (day 3 toand MC-Sp. Immunostaining of structural proteins in (A) monolayer
uclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue).
hESC, human embryonic stem cell; MC, microcarrier; MLC, myosin light
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expression of the cardiac mesoderm marker Islet-1 and
early cardiac marker homeobox protein Nkx-2.5 began on
day 3. This expression then reached its peak at day 11 and
saturated on day 13. Thereafter, the relative expression of
late cardiac markers such as α-MHC was also significantly
upregulated from day 5 and persisted throughout the
20 days’ differentiation. A high expression of myosin light
chain-2 atrial, which reached its maximum on day 11,
indicated the presence of atrial CMs. The expression of
cardiac ion channel proteins (CACNA1D, encoding the
α1D subunit of the L-type calcium channel; KCNH2,
the potassium voltage-gated channel; and HCN4, the
potassium/sodium hyperpolarisation-activated cyclic
nucleotide-gated channel 4, responsible for the pace-
maker current) was also significantly upregulated after
day 11 of the differentiation phase.
Immunofluorescence analyses were performed to de-
termine the presence of cardiac-specific proteins at day
20. The hESC monolayer-derived CMs (Figure 5A) and
hESC/MC-derived CMs (Figure 5B) both stained positive
for sarcomeric proteins – α-actinin, myosin light chain,
and cTnT – thus showing a well-organised sarcomeric
structure, a phenomenon associated with maturing CMs.Figure 6 Dose-dependent effect of E-4031 and verapamil on duration
Dose-dependent effect of E-4031 (•) and verapamil (♦) on duration of the Q
assay (conducted by ReproCELL Inc., Kanagawa, Japan). Increase in E-4031
interval by 40%, while increase in verapamil concentration from 10 nM to 3
bryonic stem cell/microcarrier aggregates in spinner cultures.Functional characterisation
Beating CMs from cultures at day 20 were seeded onto a
multielectrode plate, which served to test their response
to pharmacologically active compounds. When the se-
lective hERG inhibitor E-4031 was introduced, a dose-
dependent prolongation of the QT interval was observed
from a threshold of 10 nM, peaking at 300 nM (rising
to over 140% from 100%; Figure 6). In contrast, verap-
amil (L-type calcium channel blocker) induced a dose-
dependent reduction of the QT interval at concentrations
ranging from 10 nM to 3 μM to 56% of the starting condi-
tion (Figure 6). Similar responses were observed using the
induced pluripotent stem-derived cell line ReproCardio 2
(see Additional file 8). It is important to note that the QT-
interval duration is directly proportional to the action
potential duration in cardiomyocytes [42,43,47]. These
results demonstrated that hESC/MC-derived CMs ge-
nerated by MC-Sp responded normally [40] to these anti-
arrhythmic drugs.
Discussion
A recent review by our group discussed in detail the key
issues for large-scale production of human CMs from
hPSCs [31]. One of the limitations of differentiatingof the QT interval of differentiated MC-Sp cardiomyocytes.
T interval of differentiated MC-Sp cardiomyocytes using the QTempo
concentration from 10 to 300 nM results in prolongation of the QT
μM results in reduction of the QT interval by 56%. MC-Sp, human em-
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fold [31,48]. This is similar to our data from the present
study, showing about twofold expansion (Table 1; see
Additional file 7). The strategy for CM production
would thus be biphasic, involving hESC propagation to
generate significant cell numbers, followed by differenti-
ation to CMs. Two hESC propagation platforms (Figure 1)
were used in this study: monolayer and MC/aggregate
hESC cultures. Conventional MNL have been widely em-
ployed for hESC expansion, but the increase in cell density
is restricted to the available culture area [31,34]. MCs are
characterised by high surface-to-volume ratio, which al-
lows for high-density cell culture, and the possibility of
scaling up has been demonstrated by several groups using
spinner flasks [31,34,49,50]. The present study demon-
strates that MC spinner cultures achieved 15.4-fold pluri-
potent HES3 expansion (similar to our previous study
[35]), which is fivefold more than those achieved in MNL
(Table 1). There is further room for improvement in this
scalable process through controlled feeding strategies to
obtain higher cell expansion [36].
Having established a scalable hESC propagation me-
thod, a suitable CM differentiation platform should be
developed [31]. The present report compares five modes
of differentiation, where the CM/hESC yield was ranked
as follows: MC-Sp >>MNL > (MC-Rp ≈MC-SS) >MC-AS
(Table 1). The conjoint propagation and differentiation
protocol (MC-Sp) eliminates the labour-intensive cutting,
size control, and replating that are required by EB cul-
ture methods [26-28]. hESC/MC aggregates (about 300 to
400 μm in size) obtained during the propagation phase are
subjected to a differentiation medium by continuing in the
same culture vessel. A simple medium change thus in-
duces the CM differentiation process from HES3 to gener-
ate cTnT-positive CMs (9.6 ± 0.3 CM/hESC in MC-Sp vs.
3.8 ± 0.2 CM/hESC in MNL; P < 0.05) and the concentra-
tion of CMs obtained (1.9 ± 0.05 × 106 CM/ml) was four-
fold higher than from MNL (0.5 ± 0.02 × 106 CM/ml;
P < 0.01) (Table 1).
Moreover, the total cell expansion (from seeding hESC
culture to final CM harvesting) in this integrated system
was about 34.3-fold, whereas in MNL the expansion was
20-fold (P < 0.05; Table 1). These differences are mainly
attributed to the three-dimensional nature of the ag-
gregate cultures as compared with the one-layer two-
dimensional nature of the MNL. The MC-based method
lends itself easily to scalable bioreactor processing, in
contrast to planar MNL, which require complex stacking
arrangements and are thus poorly suited for scalable
processes. hESC/MC-derived CMs from MC-Sp cultures
were observed to express cardiac markers associated
with cardiomyogenesis (Figures 4 and 5B), demonstrat-
ing a similar trend to that observed in hESCs differen-
tiating on MNL (Figures 4 and 5A) and followed thecardiac developmental process [51,52]. This MC-based
conjoint propagation and differentiation system is thus
overall more efficient than MNL for the high-yield pro-
duction of CMs in a reliable and robust process.
Prior studies demonstrated the significant role of
uniform-sized cell aggregates in differentiation outcomes
[27,29,38]. Reports from Zandstra’s group suggested that
the optimal aggregate size ranges from 200 to 800 μm,
where the highest percentage of contracting aggregates is
produced by 400 μm aggregates [53,54]. Another study
showed that the generation of 300 μm aggregates, using
microwells, was the most efficient method for producing
contracting cells [29]. Studies by our group also suggested
that a size distribution of 200 to 400 μm generally gives
higher cell expansion and more MHC+/SA+ cells [38].
However, that same study generated hPSC/MC aggregates
in spinner cultures from MNL, following a differentiation
protocol using SB203580, a mitogen-activated protein kin-
ase inhibitor. In short, another advantage of the present
MC-based system is its ability to generate aggregates with
specific sizes (316 μm in HES3, Table 1; and 418 μm in
H7, see Additional file 7). More importantly, the ability to
control the size of an aggregate within a scalable biopro-
cess may contribute to a more homogeneous [35], syn-
chronised differentiation [27,29,30].
A decline in cell density and viability was observed fol-
lowing the initial exposure of both HES3/MC and H7/
MC aggregates to CHIR99021, in MC-Sp (Figure 3 and
see Additional file 6). The observed cell loss may be at-
tributed to the abrupt change in culture medium, from
mTeSR™1, to differentiation medium (RPMI/B27), as well
as the toxicity of CHIR99021, when used at high concen-
trations (>10 μM) [55]. This cell loss could be alleviated
when static pauses were employed (Figure 2), in order to
prevent additional agitation-induced cell death due to
further stress arising from turbulent eddies, MC-to-
MC impacts and MC-to-container (or impeller) impacts
[56]. Dissociation of cells/MC aggregates were also ob-
served after addition of IWP2 (Figure 2). Studies showed
that IWP2 blocks Wnt protein secretion, leading to the
proteasome-mediated degradation of β-catenin; and this is
detrimental to the adherent junctions in cell–cell adhesion
complexes [57,58]. A second static pause (~16 hours) was
thus introduced to mitigate the possibility of cells dis-
lodgement from the MC due to agitation forces. In a nut-
shell, these two static pauses successfully maintained a
stable increase in the viable cell density during the diffe-
rentiation phase (Figures 2 and 3; see Additional file 6).
Although agitated MC-AS and MC-Sp are both amen-
able to control the size of the differentiating cell aggre-
gates, lower cell yields were obtained in MC-AS (0.1 vs.
1.9 × 106 CM/ml, P < 0.01; Table 1). This is attributed to
the high agitation speeds of the plates on a shaking plat-
form (110 rpm to suspend hESC/MC aggregates)
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the gentle agitation by an impeller, operating at lower
speed (30 rpm), in stirred flasks [59]. This putatively re-
sulted in poorer hESC growth and differentiation effi-
ciency, as measured in MC-AS [60]. Moreover, cells can
be seeded at 10-fold higher density (~1.5 × 106 cells/ml)
in MC-Sp, than the inoculum cell density in MNL, MC-
Rp, MC-SS, or MC-AS (~1.5 × 105 cells/ml). In addition,
the well-mixed environment of MC-Sp is better for de-
livering nutrients and oxygen to MC cell aggregates via
convection of the fluid medium [59,61]. High cell viabil-
ity is thus maintained without compromising the dif-
ferentiation efficiency, resulting in higher CM yields.
The present study further confirms previous work
from our group, describing that microcarrier cultures
facilitate higher pluripotent and differentiated cell
(neuroprogenitors) yields [32,34-36].
Quantification of the nutrient uptake and respiration
products offers evidence that the hESC energy metabo-
lism differs between the propagation and differentiation
phases. In the hESC propagation phase, the higher YLac/Glc
indicates anaerobic glycolysis (Table 2). Reports state that
stem cells favour anaerobic glycolysis for cell survival and
proliferation, but not differentiation, since they only pos-
sess immature mitochondria for energy supply in order to
control the stem cell state [62,63]. In contrast, lower
YLac/Glc (1.27 to 1.34; Table 2) during cell differenti-
ation suggests that this phase is accompanied by an
increase in the aerobic metabolism of the cells. Reports
have shown that differentiation events are associated with
the proliferation of mitochondria, which generate more
energy for the molecular machinery in response to differ-
entiation [64,65]. Another study has demonstrated that
the inhibition of Wnt signalling facilitates mitochondrial
respiration, with induction of the glycolytic switch into an
aerobic metabolism [66]. This correlates with the findings
of the present study.
This platform may potentially be improved to obtain
higher yields and purity of CM cells for clinical applica-
tions; for example, by altering the feeding regime to daily
or twice-daily medium exchange [36]. Moreover, the ad-
dition of ascorbic acid has been demonstrated to promote
cardiac differentiation and has been applied in several pro-
tocols, using hESCs and human induced pluripotent stem
cells [14,67]. To implement good manufacturing practice
production criteria, human LM could replace murine LM
for propagating and differentiating hESCs in a serum-free,
xeno-free, defined environment. Depending on the size of
the bioreactor, larger quantities of clinical-grade CMs can
thus be generated to meet therapeutic dose requirements.
Conclusion
Five methods of differentiation were compared and MC-
Sp were the best condition for scale-up and productionof hESC-derived CMs, within an integrated process of
cell propagation and subsequent differentiation. This MC-
based conjoint culture is crucial to achieving both high
cell densities (1.9 × 106 CM/ml) and high CM/hESC yields
(9.6 ± 0.3), as compared with the other tested methods.
CMs expressed cardiac-specific transcriptional factors,
structural and functional genes, and generation of cross-
striated muscle structure that recapitulate the develop-
ment ontogeny of cardiogenesis. The advantages of this
approach are: high cell yields; controlled aggregate size;
negligible labour-intensive manual intervention (time-
saving); and use of cost-effective defined chemical compo-
nents (a potential cost-saving), which has the potential to
comply with a defined good manufacturing practice bio-
process system. The scalable nature of this MC-based bio-
process under agitation is expected to provide a platform
technology for the bioreactor-based production of CMs
derived from hPSCs.Additional files
Additional file 1: Is a figure showing optimization of the
concentrations of Wnt modulators, CHIR99021 and IWP2, in MNL
(A); MC-Rp (B); and MC-SS (C). Cells were analysed for MHC and cTnT
expression by flow cytometry 20 days after initiation of differentiation.
The optimal concentrations are marked in the white box. Step 1:
optimization of CHIR99021 concentration (IWP2 concentration kept at
5 μM); Step 2: optimization of IWP2 concentrations (the optimal
concentrations of CHIR99021 were used in Step 1).
Additional file 2: Is a table presenting the sequences of primers
used for quantitative polymerase chain reaction.
Additional file 3: Is a video showing HES3 cultured as a monolayer
on a LN-coated plate (MNL) and treated with 12 μM CHIR99021 at
day 0 and 5 μM IWP2 at day 3 in RPMI/B27 medium without insulin.
Video 1 shows cardiomyocytes from day 20.
Additional file 4: Is a figure showing growth kinetics of MC stirred
spinner cultures of (A) HES3 and (B) H7 during the propagation
phase. H7 produced larger aggregates than HES3 in PLL + LN MC
spinner flask.
Additional file 5: Is a video showing integrated propagation and
differentiation of HES3 in MC culture platform (MC-Sp). Video 2
shows cardiomyocytes from day 20. Round spheres inside the cell
clumps are the MCs (diameter ≈ 100 μm).
Additional file 6: Is a figure showing growth kinetics of H7/MC
aggregates differentiating in stirred spinner cultures. The cultures
were incubated at 37°C and 5% carbon dioxide in stirring conditions,
except on day 1 and day 3, in which the cultures were incubated in
static conditions for 16 hours to reduce cell lost due to the addition of
Wnt modulators, CHIR99021 and IWP2. Feeding regime is as indicated by
arrows.
Additional file 7: Is a table presenting integrated propagation and
differentiation of H7 to cardiomyocytes in MC spinner cultures.
Additional file 8: Is a figure showing the dose-dependent effect of
E-4031 (A) and verapamil (B) on duration of the QT interval of
ReproCardio 2 induced pluripotent stem cell-derived cardiomyocytes
using the QTempo assay (conducted by ReproCELL Inc.). Results are
presented as actual measurements (•) and after correction with Bazett (■)
or Fredericia (▲) formulas. Increase in the E-4031 concentration results
in prolongation of QT intervals, while increase in the verapamil
concentration results in reduction of QT intervals.
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CM: cardiomyocytes (cardiac troponin T-positive cells) in the final cell
population; cTnT: cardiac troponin T; EB: embryoid body; FACS: fluorescence-
activated cell sorting; hESC: human embryonic stem cell; hPSC: human
pluripotent stem cell; IWP: inhibitor of Wnt production; LN: laminin;
MC: microcarrier; MC-AS: hESC/MC aggregates in agitated suspension
cultures; MC-Rp: monolayer replated cultures; MC-Sp: hESC/MC aggregates in
spinner cultures; MC-SS: hESC/MC aggregates in static suspension cultures;
MHC: myosin heavy chain; MNL: monolayer cultures; OCT4: octamer-binding
transcription factor 4; PBS: phosphate-buffered saline; PLL: poly-L-lysine;
SA: sarcomeric α-actinin.
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